Trial · NCT01078753

Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis

NCT01078753, Phase 3, Completed, Ferring Pharmaceuticals; results first posted 2011-11-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis. Trials, record NCT01078753. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01078753

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis
NCT number: NCT01078753
Status: Completed
Phases: Phase 3
Enrollment: 89 participants, actual
Lead sponsor: Ferring Pharmaceuticals
Conditions: Nocturnal Enuresis
Interventions: Desmopressin, Placebo
First posted: 2010-03-02
Last updated: 2011-11-02
Results first posted: 2011-11-02

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in the Number of Wet Nights Between Baseline and Treatment Period II	Baseline (14-day period prior to starting study treatment) and Treatment Period II (weeks 3-4 after treatment initiation).	The number of wet nights was recorded by participants (or their caregivers) in a daily diary. The difference was calculated from the number of wet nights during the 14-day Baseline Period minus the number of wet nights during the 14-day Treatment Period II.
Secondary	Change in Number of Wet Nights Between Baseline and Treatment Period I	Baseline (14-day period prior to starting study treatment) and Treatment Period I (weeks 1-2 after treatment initiation).	The number of wet nights was recorded by participants (or their caregivers) in a daily diary. The difference was calculated from the number of wet nights during the 14-day Baseline Period minus the number of wet nights during the 14-day Treatment Period I.
Secondary	Change in Number of Wet Nights Between Treatment Periods I and II	Treatment Period I (weeks 1-2) and Treatment Period II (weeks 3-4)	The number of wet nights was recorded by participants (or their caregivers) in a daily diary. The difference was calculated from the number of wet nights during the 14-day Treatment Period I minus the number of wet nights during the 14-day Treatment Period II.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in the Number of Wet Nights Between Baseline and Treatment Period II	Baseline (14-day period prior to starting study treatment) and Treatment Period II (weeks 3-4 after treatment initiation).	The Full Analysis Set (FAS) included all participants who received at least one dose of study treatment, satisfied all the major eligibility criteria and for whom efficacy data was obtained.	wet nights	LEAST_SQUARES_MEAN
SECONDARY	Change in Number of Wet Nights Between Baseline and Treatment Period I	Baseline (14-day period prior to starting study treatment) and Treatment Period I (weeks 1-2 after treatment initiation).	The Full analysis set.	wet nights	LEAST_SQUARES_MEAN
SECONDARY	Change in Number of Wet Nights Between Treatment Periods I and II	Treatment Period I (weeks 1-2) and Treatment Period II (weeks 3-4)	The full analysis set.	wet nights	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in the Number of Wet Nights Between Baseline and Treatment Period II	Desmopressin	3.264	95% Confidence Interval 2.126 to 4.402	wet nights
Change in the Number of Wet Nights Between Baseline and Treatment Period II	Placebo	1.451	95% Confidence Interval 0.333 to 2.570	wet nights
Change in Number of Wet Nights Between Baseline and Treatment Period I	Desmopressin	2.946	95% Confidence Interval 1.815 to 4.078	wet nights
Change in Number of Wet Nights Between Baseline and Treatment Period I	Placebo	1.317	95% Confidence Interval 0.205 to 2.428	wet nights
Change in Number of Wet Nights Between Treatment Periods I and II	Desmopressin	0.318	95% Confidence Interval -0.653 to 1.289	wet nights
Change in Number of Wet Nights Between Treatment Periods I and II	Placebo	0.135	95% Confidence Interval -0.819 to 1.088	wet nights

Source ClinicalTrials.gov

Participant flow16

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Treatment Period I	STARTED	Desmopressin	45
Treatment Period I	STARTED	Placebo	44
Treatment Period I	Full Analysis Set	Desmopressin	44
Treatment Period I	Full Analysis Set	Placebo	44
Treatment Period I	COMPLETED	Desmopressin	45
Treatment Period I	COMPLETED	Placebo	44
Treatment Period I	NOT COMPLETED	Desmopressin	0
Treatment Period I	NOT COMPLETED	Placebo	0
Treatment Period II	STARTED	Desmopressin	45
Treatment Period II	STARTED	Placebo	44

1 to 10 of 16Source ClinicalTrials.gov

See all 16 participant flow

Adverse events46

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Empyema	Infections and infestations	Desmopressin	0	45
other	Empyema	Infections and infestations	Placebo	1	44
other	Nasopharyngitis	Infections and infestations	Desmopressin	6	45
other	Nasopharyngitis	Infections and infestations	Placebo	6	44
other	Tonsillitis	Infections and infestations	Desmopressin	1	45
other	Tonsillitis	Infections and infestations	Placebo	0	44
other	Upper respiratory tract infection	Infections and infestations	Desmopressin	1	45
other	Upper respiratory tract infection	Infections and infestations	Placebo	0	44
other	Headache	Nervous system disorders	Desmopressin	1	45
other	Headache	Nervous system disorders	Placebo	0	44

1 to 10 of 46Source ClinicalTrials.gov

See all 46 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Desmopressin
Total, all-cause mortality	Placebo
Total, other adverse events	Desmopressin	18	45
Total, other adverse events	Placebo	14	44
Total, serious adverse events	Desmopressin	0	45
Total, serious adverse events	Placebo	0	44

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
40728007	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Desmopressin vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01078753

GET https://conductscience.org/api/trials/v1/NCT01078753/events?page=2

API reference For AI assistants